20250210-东兴证券-中广核技-000881.SZ-非动力核技术龙头迈向高端_19页_2mb

Summary of China Nuclear Technique Development Co., Ltd. (000881SZ)

Company Overview: China Nuclear Technique Development Co., Ltd. (000881SZ) is the first stock of China's non-power nuclear technology application industry, serving as a development platform for the group's non-power nuclear technology application sector. The company operates in non-power nuclear technology innovation, focusing on materials, accelerator technologies, and sterilization services.

Business Performance:

• In 2022-2024, the company's revenue fluctuated due to market demand and raw material price hikes.
• The key business—high-end materials—faced profit pressure from increased input costs, while new initiatives like proton therapy systems contributed to future growth potential.

Nuclear Technology Application Outlook:

• Non-power nuclear technology applications are poised for significant growth, with policy support targeting a RMB 400 billion market value by 2026.
• Key areas include medical sterilization, advanced materials, and radiation processing, with the firm aiming to lead in high-value products like proton therapy.

Financial Forecast:

• The company's projected net profit for 2024-2026 ranges from -RMB 3.13 billion to RMB 1.9 billion, with a current PE ratio of 5503x for 2025.
• Despite the high valuation, analysts recommend the stock based on its potential in high-energy accelerator technology and market expansion.

Risks:

• Downside risks include policy changes, demand fluctuations, and elevated valuation concerns.

Conclusion: The company is positioned to capitalize on nuclear technology advancements but will navigate economic and competitive challenges.